Cerulean Reports Fourth Quarter 2015 Corporate Highlights and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Leerink Partners Cuts Price Target on Cerulean Pharma (CERU) to $8; Reiterates Outperform
March 11, 2016 7:20 AM ESTLeerink Partners maintained an Outperform rating on Cerulean Pharma (NASDAQ: CERU), and cut the price target to $8.00 (from $10.00), following the company's 4Q.
Analyst Michael Schmidt commented, "CERU reported 4Q results and provided an update on its clinical nanoparticle drug-conjugate (NDC) pipeline consisting of... More
